Soligenix Revenue
Biotechnology Research • 
West Windsor, New Jersey, United States • 21-50 Employees
Soligenix revenue & valuation
| Annual revenue | $119,371 |
| Revenue per employee | $5,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $381,987 |
| Total funding | $20,800,000 |
Key Contact at Soligenix
Andrea Haulenbeek
Associate Director, Regulatory Affairs
Company overview
| Headquarters | 29 Emmons Drive, Suite B-10, Princeton, NJ 08540, US |
| Phone number | +16095388200 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, Oncology, Orphan Diseases, Ebola, Infectious Disease, Rare Disease, Head And Neck Cancer, Heat Stable Vaccines, Acute Radiation Enteritis, Acute Radiation Syndrome, Antibiotic Resistant Infectious Disease, Cutaneous T-Cell Lymphoma, Hypericin, Innate Defense Regulator, Melioidosis, Pediatric Crohn’S Disease, Photodynamic Therapy, Ricin Exposure, Oral Mucositis, Rare Cancers, Ricin Toxin Vaccine, Bioterrorism |
| Founded | 1987 |
| Employees | 21-50 |
| Socials |
Soligenix Email Formats
Soligenix uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@soligenix.com), used 78.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@soligenix.com | 78.6% |
{first name}{last name} | johndoe@soligenix.com | 21.4% |
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Soligenix has 14 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Soligenix's funding history, including investment rounds, total capital raised, and key backers.
Soligenix Tech Stack
Discover the technologies and tools that power Soligenix's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
JavaScript libraries
JavaScript libraries
CDN
Font scripts
SEO
JavaScript libraries
Programming languages
Security
Blogs
Italy
United Arab Emirates
Israel
Canada
India
Austria
Iran, Islamic Republic of
Frequently asked questions
4.8
40,000 users
